Wall Street analysts forecast that Aphria Inc (NYSE:APHA) will announce earnings per share of ($0.01) for the current quarter, Zacks reports. Two analysts have made estimates for Aphria’s earnings, with the highest EPS estimate coming in at $0.01 and the lowest estimate coming in at ($0.02). Aphria reported earnings of ($0.15) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 93.3%. The firm is scheduled to issue its next earnings results on Monday, April 20th.

On average, analysts expect that Aphria will report full-year earnings of $0.03 per share for the current financial year, with EPS estimates ranging from ($0.11) to $0.10. For the next fiscal year, analysts forecast that the firm will report earnings of $0.11 per share, with EPS estimates ranging from ($0.07) to $0.30. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Aphria.

Aphria (NYSE:APHA) last released its quarterly earnings results on Tuesday, October 15th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.10. The business had revenue of $126.10 million for the quarter, compared to analysts’ expectations of $131.15 million. The firm’s revenue for the quarter was up 848.1% compared to the same quarter last year.

A number of equities research analysts recently issued reports on the stock. Bank of America assumed coverage on shares of Aphria in a research note on Monday. They set a “neutral” rating on the stock. Zacks Investment Research downgraded shares of Aphria from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 6th. CIBC raised shares of Aphria from an “underperform” rating to a “neutral” rating and set a $7.00 price target on the stock in a research note on Tuesday. ValuEngine downgraded shares of Aphria from a “buy” rating to a “hold” rating in a research note on Thursday, December 5th. Finally, Cantor Fitzgerald assumed coverage on shares of Aphria in a research note on Tuesday, November 5th. They set an “overweight” rating and a $10.40 price target on the stock. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $12.09.

A number of hedge funds have recently bought and sold shares of the business. Dubuque Bank & Trust Co. bought a new position in Aphria during the fourth quarter valued at $304,000. K2 Principal Fund L.P. increased its position in Aphria by 116.8% during the third quarter. K2 Principal Fund L.P. now owns 25,200 shares of the company’s stock valued at $173,000 after acquiring an additional 175,200 shares during the last quarter. Barclays PLC increased its position in Aphria by 87.9% during the third quarter. Barclays PLC now owns 47,677 shares of the company’s stock valued at $248,000 after acquiring an additional 22,305 shares during the last quarter. Virtu Financial LLC increased its position in Aphria by 14.9% during the third quarter. Virtu Financial LLC now owns 18,365 shares of the company’s stock valued at $95,000 after acquiring an additional 2,380 shares during the last quarter. Finally, First Allied Advisory Services Inc. bought a new position in Aphria during the third quarter valued at $57,000. Institutional investors and hedge funds own 9.60% of the company’s stock.

Aphria stock traded up $0.02 during mid-day trading on Friday, reaching $5.26. 284,892 shares of the company’s stock traded hands, compared to its average volume of 5,287,557. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -47.87, a PEG ratio of 5.22 and a beta of 2.78. The stock has a 50 day moving average of $4.95 and a two-hundred day moving average of $5.61. Aphria has a 12-month low of $3.76 and a 12-month high of $10.95.

Aphria Company Profile

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Recommended Story: Profit Margin

Get a free copy of the Zacks research report on Aphria (APHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.